Travere Therapeutics (TVTX) Return on Capital Employed (2013 - 2026)

Travere Therapeutics has reported Return on Capital Employed for 14 years, with the latest figure at 12.55% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 4587.0% year-over-year to 12.55%; the trailing twelve-month figure through Mar 2026 stood at 12.55% (up 4587.0% YoY), and the FY2025 full-year result was 14.29%, up 5170.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 12.55%, up from 15.25% in the prior quarter.
• The five-year high for Return on Capital Employed was 12.55% in Q1 2026, with the low at 105.8% in Q3 2024.
• Historically, Return on Capital Employed has averaged 54.65% across 5 years, with a median of 57.39% in 2022.
• Annual changes were most pronounced in 2024 — Return on Capital Employed sank 4681 bps — and 2025, when it jumped 8368 bps.
• Travere Therapeutics' Return on Capital Employed stood at 57.39% in 2022, then dropped by 7 bps to 61.32% in 2023, then sank by 52 bps to 92.92% in 2024, then soared by 84 bps to 15.25% in 2025, then climbed by 18 bps to 12.55% in 2026.
• The last three Return on Capital Employed figures came in at 12.55% (Q1 2026), 15.25% (Q4 2025), and 22.13% (Q3 2025), per Business Quant data.